Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma - Episode 12

Triple Combination Therapies in RCC: Clinical Trial Insights

December 19, 2023

Ulka Vaishampayan, MD, Alan Tan, MD, Laurence Albiges, MD, PhD, Neeraj Agarwal, MD, Matthew T. Campbell, MD, MS, Benjamin Maughan, MD, PharmD

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP. 2: Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP. 3: Imaging and Staging Considerations in Renal Cell Carcinoma

EP. 4: Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

EP. 5: Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP. 6: Comparing Treatment Combinations in Renal Cell Carcinoma

EP. 7: Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP. 8: Sequencing and Second-Line Therapy in RCC: Patient Scenario

EP. 9: Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

EP. 10: Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP. 11: Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

Now Viewing

EP. 12: Triple Combination Therapies in RCC: Clinical Trial Insights

EP. 13: Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment